On Tuesday, Regulus Therapeutics Inc (NASDAQ: RGLS) was -0.25% drop from the session before settling in for the closing price of $7.85. A 52-week range for RGLS has been $0.83 – $8.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -10.71% over the last five years. When this article was written, the company’s average yearly earnings per share was at -50.41%. With a float of $52.53 million, this company’s outstanding shares have now reached $65.50 million.
The firm has a total of 34 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of -14718.24%, and the pretax margin is -13634.41%.
Regulus Therapeutics Inc (RGLS) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Regulus Therapeutics Inc stocks. The insider ownership of Regulus Therapeutics Inc is 20.70%, while institutional ownership is 67.85%. The most recent insider transaction that took place on Jan 30 ’25, was worth 54,260. In this transaction Chief Executive Officer of this company bought 50,000 shares at a rate of $1.09, taking the stock ownership to the 260,808 shares. Before that another transaction happened on Jan 30 ’25, when Company’s Director bought 19,610 for $1.06, making the entire transaction worth $20,787. This insider now owns 22,169 shares in total.
Regulus Therapeutics Inc (RGLS) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -50.41% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -13.90% during the next five years compared to 40.21% growth over the previous five years of trading.
Regulus Therapeutics Inc (NASDAQ: RGLS) Trading Performance Indicators
You can see what Regulus Therapeutics Inc (RGLS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 10.52.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.88, a number that is poised to hit -0.24 in the next quarter and is forecasted to reach -1.55 in one year’s time.
Technical Analysis of Regulus Therapeutics Inc (RGLS)
Analysing the last 5-days average volume posted by the [Regulus Therapeutics Inc, RGLS], we can find that recorded value of 7.94 million was better than the volume posted last year of 1.52 million. As of the previous 9 days, the stock’s Stochastic %D was 93.98%. Additionally, its Average True Range was 0.47.
During the past 100 days, Regulus Therapeutics Inc’s (RGLS) raw stochastic average was set at 94.98%, which indicates a significant increase from 94.11% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 350.44% in the past 14 days, which was higher than the 167.53% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.34, while its 200-day Moving Average is $1.71. Now, the first resistance to watch is $7.85. This is followed by the second major resistance level at $7.88. The third major resistance level sits at $7.89. If the price goes on to break the first support level at $7.81, it is likely to go to the next support level at $7.80. Now, if the price goes above the second support level, the third support stands at $7.77.
Regulus Therapeutics Inc (NASDAQ: RGLS) Key Stats
There are 66,243K outstanding shares of the company, which has a market capitalization of 518.69 million. As of now, sales total 0 K while income totals -46,360 K. Its latest quarter income was 0 K while its last quarter net income were -12,790 K.
